# A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.

Study · id `cardio:ct-nct06431763` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06431763](<https://clinicaltrials.gov/study/NCT06431763>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06431763

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 402 participants.

## Technical summary

Registry record NCT06431763. Randomized; no masking; primary purpose treatment. Start 2024-06-21 (actual); primary completion 2025-12-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 402 participants (enrolled count; ClinicalTrials.gov record NCT06431763, source copy `cardio:ctgov-nct06431763-2026-07-29`, retrieved 2026-10-31)
- Started: 2024-06-21 (actual) (ClinicalTrials.gov record NCT06431763, source copy `cardio:ctgov-nct06431763-2026-07-29`, retrieved 2026-10-31)
- Primary completion: 2025-12-01 (actual) (ClinicalTrials.gov record NCT06431763, source copy `cardio:ctgov-nct06431763-2026-07-29`, retrieved 2026-10-31)
- Completion: 2026-01-02 (actual) (ClinicalTrials.gov record NCT06431763, source copy `cardio:ctgov-nct06431763-2026-07-29`, retrieved 2026-10-31)
- Countries: Germany (ClinicalTrials.gov record NCT06431763, source copy `cardio:ctgov-nct06431763-2026-07-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06431763-2026-07-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Investigate LDL-cholesterol Lowering With Inclisiran Compared to Bempedoic Acid in Patients With Atherosclerotic Cardiovascular Disease.
- Condition: Hypercholesterolemia
- Intervention (Drug): Inclisiran sodium
- Intervention (Drug): BPA
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: dd8c92cd8904c784b4fa78f47d54c7440c8bc2415a284410ad6a6cba83c98351
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
